Clinical trials: Patients With Major Depressive Disorder
Depression, Alcoholism
Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism
We will study patients with a current major depressive episode, comorbid alcoholism and a history of a past suicide attempt. All subjects with alcohol dependence will be evaluated for risk of alcohol withdrawal prior to…
- Conditions
- Depression, Alcoholism, Suicidal Behavior
- Trial name
- NCT00449007
- Testing
- fluoxetine, bupropion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder (MDD)
A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder
A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial, aim to evaluate the efficacy and safety of dextromethorphan and bupropion sustained-release tablets in Chinese adult patients with major depressive…
- Trial name
- NCT06958692
- Testing
- Dextromethorphan and Bupropion Sustained-Release Tablets
- Where
- China
- Volunteers
- 388 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Major Depressive Disorder
Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity
This 26-week long, double-blinded randomized clinical trial aims to investigate the effects of semaglutide once-weekly vs. placebo on depressive symptoms in 116 patients with Major Depressive Disorder (MDD) and co-existing…
- Trial name
- SEMAMOOD (NCT07136714)
- Testing
- Semaglutide Injectable Product
- Where
- Denmark
- Volunteers
- 116 people
- Sponsor
- Nordsjaellands Hospital
Depression
Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
Trial to determine the maximum tolerated dose (MTD) based on safety and tolerability of MK-8777 (Org 26576, SCH 900777) in participants with major depressive disorder.
- Trial name
- NCT00610649
- Testing
- MK-8777
- Volunteers
- 54 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depression, Cancer
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions…
- Conditions
- Major Depression, Cancer, Diabetes, Cardiovascular Diseases
- Trial name
- NCT01803711
- Testing
- Desvenlafaxine, Omega 3 Fatty acids
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- UConn Health
Depressive Disorder
Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients
Phase III, open label, randomised, multicentre, blind for evaluators clinical trial to evaluate the efficacy of esketamine nasal spray at flexible dosis compared to aripiprazole in elderly participants (>60 years) who suffer from…
- Trial name
- CESAR (NCT07153406)
- Testing
- Experimental regimen, Control regimen
- Where
- 9 sites in Spain
- Volunteers
- 220 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Depressive Disorder, Major
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of Seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia…
- Trial name
- NCT04532749
- Testing
- Seltorexant
- Where
- 80 sites in United States, Argentina and 8 more
- Volunteers
- 212 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder
Phase advance of HRV will be anticipated in agomelatine group. It is anticipated that both agomelatine and floxentine will increase HRV at the end of the treatment.
- Trial name
- NCT00451490
- Testing
- Agomelatine, Fluoxentine
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- National Taiwan University Hospital
Major Depressive Disorder
Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation in Patients With Treatment-resistant Depression
Major depressive disorder (MDD) is a significant public health problem. Existing treatment modalities are not always sufficient to alleviate this disorder. Treatment refractoriness is a common clinical problem.
- Trial name
- NCT02141776
- Testing
- Transcranial direct current stimulation (t-DCS)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Florida
Anxiety Disorders, Major Depressive Disorder
Acquisition and Analysis of Relationships Between Longitudinal Emotional Signals Produced by an Artificial Intelligence Algorithm and Self-questionnaires Used in the Psychiatric Follow-up of Patients With Mood and/or Anxiety Disorders: a Real-Environment Study.
The worldwide prevalence of anxiety and depression increased massively during the pandemic, with a 25% rise in the number of patients suffering from psychological distress.
- Trial name
- EMOACQ-1 (NCT05988840)
- Testing
- Acquisition and analysis of relationships between Longitudinal Emotional Signals produced by a software and Self-questionnaires.
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Emobot
Major Depressive Disorder
Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
To examine the efficacy and safety of aripiprazole versus placebo as an adjunctive therapy co-administered with either an selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) in…
- Trial name
- NCT00876343
- Testing
- Aripiprazole (Fixed dose), Aripiprazole (Titrated dose)
- Where
- 8 sites in Japan
- Volunteers
- 586 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Depression, Pain
Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain
The purposes of this study are to determine whether an investigational drug can help patients suffering from major depression with pain symptoms, and gather data on the safety of the investigational drug including any side…
- Trial name
- NCT00036335
- Testing
- Duloxetine Hydrochloride
- Where
- 25 sites in United States
- Volunteers
- 286 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder in Remission, Major Depression in Remission
Seasonality, Chronotype, Impulsivity, and Suicidality in Mood Disorder Patients
The aim of the study is to examine the seasonal variation of suicidal ideation in patients with mood disorders and the trajectory of impulsivity and suicidal ideation in patients with higher seasonality.
- Trial name
- NCT07857213
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Istanbul University - Cerrahpasa
Major Depression, Tobacco Addiction
Transcranial Magnetic Stimulation in Patients with Dual Disorders
According to the WHO, 280 million people are diagnosed with depression, the prevalence of which is almost twice as high in women as in men, with the incidence among young people increasing in recent years.
- Trial name
- NCT06765824
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- Spain
- Volunteers
- 36 people
- Sponsor
- Cardenal Herrera University
Major Depressive Episode, Major Depressive Disorder
Patient-oriented Randomized Pragmatic Feasibility Trial With rTMS in Depression and Anxiety
This trial compares intermittent theta-burst stimulation (iTBS) to low frequency repetitive transcranial magnetic stimulation (LFR) in regards to depression and anxiety outcomes in 100 patients with treatment resistant depression…
- Trial name
- PORT (NCT05028738)
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Depression
A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
- Trial name
- NCT06259526
- Testing
- JS1-1-01 low-dose group, JS1-1-01 high-dose group, Active drug group
- Where
- 17 sites in China
- Volunteers
- 267 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Major Depressive Disorder, Irritability
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
To explore the anti-impulsive and anti-aggressive properties of brexpiprazole in a naturalistic setting of depressed patients with irritability.
- Trial name
- NCT01942785
- Testing
- Brexpiprazole
- Where
- 15 sites in United States
- Volunteers
- 55 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder
All subjects completing the randomized treatment period in Protocol NS2014-1 will discontinue study drug and be asked to provide consent to be followed in this 6-month study, at their final safety visit.
- Trial name
- NCT02724735
- Testing
- NSI-189
- Where
- 12 sites in United States
- Volunteers
- 220 people
- Sponsor
- Neuralstem Inc.
Major Depressive Disorders
N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders
The aim of this study is to evaluate the efficacy of N-acetylcysteine (NAC) add-on to antidepressant medication in treating patients who do not relieve during standard antidepressant treatment for 6 weeks at least.
- Trial name
- NCT02972398
- Testing
- N-acetylcysteine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tianjin Anding Hospital
Anxiety Disorders, Major Depression
CBT vs RTW Intervention for Patients With Common Subclinical Mental Illness in Primary Care
Background: Common mental illness, such as anxiety disorders and depression, is the main cause for sick leave in Sweden. Cognitive behavior therapy (CBT) has been shown to be effective in alleviating target symptoms of these…
- Conditions
- Anxiety Disorders, Major Depression, Stress Disorders, Primary Insomnia
- Trial name
- NCT01667809
- Testing
- Cognitive behavior therapy, Return to work
- Where
- Sweden
- Volunteers
- 5 people
- Sponsor
- Karolinska Institutet